The clinical observation of relapsed or refractory acute myeloid leukemia in patients with high CD117 expression but no FLT3-ITD mutation treated with sorafenib alone / 天津医药

@#Objective To make a primary investigation of outcomes in relapsed or refractory (R/R) acute myeloid leukemia (AML) patients who were FLT3-ITD mutation negative and treated with sorafinib alone. Methods The clinical responses and survival of R/R AML patients who underwent sorafenib treatment only were retrospectively analyzed. The side effects and response results were assessed according to common terminology criteria for adverse events (CTCAE) v 4.0 from US National Institutes of Health and NCCN guideline. Results Four out of seven patients achieved complete remission by sorafenib treatment alone. The median time required for remission was 36 days in the four patients. Among them, only 1 patient stopped the maintenance treatment because of side effect of serious skin lesion. Three patients showed no response to sorafenib, including 2 accepted stem cell transplantation and 1 retrieved to salvage chemotherapy. All of them achieved complete remission later. One patient developed grade 1 adverse event of liver. Another one developed grade 3 skin lesion. All patients experienced neutropenia of more than 7 days without unendurable infections and early deaths. The median follow-up time for the whole cohort was more than 22 months. Three patients passed away for relapse of AML and their disease-free survival time with sorafenib ranged from 2 to 20 months. All four patients accepted stem cell transplantation were still surviving no matter whether or not they were responsive to sorafinib before. The median survival time for these seven patients was 650 days. Conclusion The R/R AML patients with negative FLT3-ITD mutation and high expression of CD117 treated with sorafenib alone have good remission and long term survival.

Therapeutic effect of torasemide combined small dose dopamine on patients with refractory heart failure/ / 心血管康复医学杂志

Objective: To observe therapeutic effect of torasemide combined small dose dopamine on patients with refractory heart failure (RHF). Methods: A total of 146 RHF patients, who were treated in our hospital from Jan 2015 to Sep 2016, were selected. According to random number table, they were randomly and equally divided into torasemide group and combined treatment group (received torasemide combined small dose dopamine), both groups were treated for 7d. Left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDd), 6min walking distance (6MWD), levels of interleukin 6 (IL-6) and tumor necrosis factorα (TNF-α) before and after treatment, and total effective rate were measured and compared between two groups. Results: Compared with before treatment, after treatment, there were significant rise in LVEF and 6 MWD, and significant reductions in LVEDd, levels of IL-6 and TNF-αin two groups, P=0. 001 all; compared with torasemide group after 7d treatment, there were significant rise in LVEF [(30. 69±4. 52) ％ vs. (36. 29±4. 86) ％]and 6MWD [(271. 21±48. 32) m vs. (322. 45±56. 34) m], and significant reductions in LVEDd [(54. 17±7. 64) mm vs. (46. 52±6. 52) mm], levels of IL-6 [(34. 65±6. 13) μg/ml vs. (26. 18±4. 53) μg/ml]and TNF-α [(50. 27±8. 74) μg/ml vs. (37. 48± 7. 04) μg/ml]in combined treatment group, P=0. 001 all. Total effective rate of combined treatment group was significantly higher than that of torasemide group (90. 4％ vs. 71. 2％, P=0. 03). Conclusion: Torasemide combined small dose dopamine can significantly reduce levels of IL-6 and TNF-α, improve cardiac function and therapeutic effect in RHF patients, which is worth extending.

Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To study the efficacy and safety of sorafenib combined with low dose cytarabine for treating patients with FLT3(+) relapsed and refractory acute myeloid leukemia (FLT3(+) RR-AML).</p><p><b>METHODS</b>Seven patients with FLT3(+) RR-AML were treated with sorafenib and low dose cytarabine. The curative rate and adverse effects were observed in these patients.</p><p><b>RESULTS</b>Out of 7 RR-AML patients after treatment, 5 patients achieved complete remission (CR), 2 patients achieved partial remission (PR), and the overall response rate (ORR) after one course of therapy was 100%. No severe bleeding, nausea, vomiting and other side effects were found in these patients.</p><p><b>CONCLUSION</b>Sorafenib combined with low dose cytarabine can effectively induce the remission of FLT3(+) RR-AML patients, and is worth for further clinical trails to verify its safty and efficiency.</p>

Silencing of survivin gene enhances chemosensitivity of human tongue cancer cell line Tca8113 to cisplatin / 中华口腔医学杂志

<p><b>OBJECTIVE</b>To investigate the effects of survivin short hairpin RNA (shRNA) on survivin expression, cell apoptosis, and chemosensitivity of human tongue cancer cell Tca8113 to cisplatin.</p><p><b>METHODS</b>Survivin-directed shRNA plasmid vector was delivered into Tca8113 cells with lipofectamine(TM) 2000 reagent. Survivin expression was detected with the reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. Flow cytometry was used to examine cell apoptosis, and the sensitivity to anticancer agents was evaluated by methyl thiazolyl tetrazolium (MTT) assay.</p><p><b>RESULTS</b>After survivin shRNA vector transfection in Tca8113 cells, the expression of mRNA/protein declined significantly, and the apoptotic rate increased in time-dependent manner up to 37.9% at 48 hours. RNAi-mediated survivin reduction selectively inhibited growth and enhanced chemosensitivity of cisplatin but not of 5-fluorouracil.</p><p><b>CONCLUSIONS</b>Survivin shRNA could inhibit the expression of survivin mRNA and it's protein and enhance the chemosensitivity of cisplatin.</p>

Role of survivin gene on the apoptosis of Tca8113 cells induced by cisplatin / 华西口腔医学杂志

<p><b>OBJECTIVE</b>To observe the induction of apoptosis of cisplatin (DDP) to oral squamous cell carcinoma cell line (Tca8113) in vitro and study the role of Survivin on the apoptosis of Tca8113 cells induced by cisplatin.</p><p><b>METHODS</b>The inhibitory effects of different doses of DDP on Tca8113 cells were assayed with MTT test. Apoptosis was determined by flow cytometry. The expression of Survivin was detected by RT-PCR and immunocytochemistry.</p><p><b>RESULTS</b>Cisplatin obviously inhibited Tca8113 cells growth in a dose and time dependent manner. The apoptotic index showed the similar trend. Survivin gene expression was decreased with increasing of time and reached the lowest level at 24 hours after DDP treatment, then increased after that time.</p><p><b>CONCLUSION</b>Cisplatin gene can effectively induce apoptosis in Tca8113 cells and the inhibition of Survivin gene expression may play a critical role on Tca8113 cell apoptosis induced by cisplatin.</p>